Primary care provider Harper Health has collaborated with genetic health solutions provider OpenDNA to offer patients access to polygenic and monogenic screening.
This partnership aims to deliver insights into cancer, cardiovascular, and other health condition risks through OpenDNA’s suite of tests, TotalRisk+, CardioRisk+, and CancerRisk+.
Go deeper with GlobalData
Leveraging AI technology, these tests analyse a person’s DNA alongside clinical attributes, evaluating their risk for various health conditions.
The outcomes are analysed using AI models and integrated into the electronic medical record (EMR) and physician workflow via an interactive user interface.
The information collected from the tests will allow individuals and healthcare providers to make “informed” decisions regarding lifestyle modifications, treatment alternatives, and preventive care.
The tests encompass both monogenic risks, stemming from a single gene; and polygenic risks, influenced by several genes.
The TotalRisk+ test includes monogenic cancer screening and the CardioRisk+ test specifically assesses the risk for cardiovascular conditions, including heart attacks and diabetes. CancerRisk+ screens for several types of cancer, including prostate, colon, and breast cancer.
Individuals at Harper Health can now undergo these genetic screening tests with a cheek swab process with the help of their physician.
Outcomes are expected within two weeks, after which Harper Health physicians will assist individuals in interpreting the findings and creating “personalised” health plans, depending on their risk profiles.
Harper Health CEO and founder Dr William Harper said: “By partnering with OpenDNA, we can now offer genetic screening that empowers our patients to take proactive steps towards managing their health and preventing future illness.
“Understanding individual risk profiles enables our physicians to provide more targeted and effective preventive care recommendations.”
